Skip to main content

Table 3 Main efficacy outcomes overall and at the recommended phase II dose

From: Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial

  Recommended phase II dose Entire study cohort
N % 95% CI N % 95% CI
Objective response at 2 cycles 1/14 7% 0–34% 2/28 7% 1–24%
Non-progression at 2 cycles 8/14 57% 29–82% 12/28 43% 24–63%
Growth modulation index≥1.3 4/14 29% 8–58% 7/27 26% 11–46%
Median progression-free survival (months) N = 14 2.9 m 1.5–5.1 N = 28 2.1 m 1.6–3.7
Median overall survival (months) N = 14 6.8 m 3.7–11.1 N = 28 8.2 m 5.1–11.7